Tymlos

Chemical Nameabaloparatide
Dosage FormInjection (subcutaneous; 3120 mcg/1.56 mL)
Drug ClassHormones
SystemMusculoskeletal
CompanyRadius Health Inc
Approval Year2017

Indication

  • To treat osteoporosis in postmenopausal women at high risk of fracture.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tymlos (abaloparatide) Prescribing Information2018Radius Health, Inc., Waltham, MA